Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
Zoetis Inc. Class A (ZTS)
Last zoetis inc. class a earnings: 2/13 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.zoetis.com
Company Research
Source: Business Wire
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well tolerated, including by cats identified with kidney disease at IRIS stage 1, 2 or 31. Portela is also approved in the European Union (EU), and Zoetis anticipates making Portela commercially available in Canada and the EU in 2026.“Health Canada’s approval of Portela marks a significant step forward in managing osteoarthritis-related pain in cats,” said Rob Polzer, Ph.D., Executive Vice President and President, Research and Development at Zoetis. “Thanks to Portela’s long-lasting antibody and
Show less
Read more
Impact Snapshot
Event Time:
ZTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZTS alerts
High impacting Zoetis Inc. Class A news events
Weekly update
A roundup of the hottest topics
ZTS
News
- Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats [Yahoo! Finance]Yahoo! Finance
- Zoetis Inc. (ZTS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Zoetis (NYSE:ZTS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $160.00 price target on the stock.MarketBeat
- Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript [Seeking Alpha]Seeking Alpha
- Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation WebcastBusiness Wire
ZTS
Earnings
- 11/4/25 - Beat
ZTS
Sec Filings
- 12/2/25 - Form 3
- 12/2/25 - Form 4
- 12/2/25 - Form 8-K
- ZTS's page on the SEC website